Hepatopatía crónica inmune-like por imatinib

Víctor Blázquez-Ávila; Laura Rodríguez-Martín; María Concepción Álvarez-Cañas; Natalia de las Heras-Rodríguez

doi:10.32818/reccmi.a9n3a4

Imatinib-induced immune-like chronic liver disease

Authors

Víctor Blázquez-Ávila Digestive System Service, University of León Healthcare Complex, León, Spain https://orcid.org/0009-0009-9532-9928
Laura Rodríguez-Martín Digestive System Service, University of León Healthcare Complex, León, Spain
María Concepción Álvarez-Cañas Pathological Anatomy Service, University of León Healthcare Complex, León, Spain https://orcid.org/0009-0001-3600-0868
Natalia de las Heras-Rodríguez Hematology Service, University of León Healthcare Complex, León, Spain

DOI:

https://doi.org/10.32818/reccmi.a9n3a4

Keywords:

fibrosis, imatinib, liver damage, receptor tyrorine kinase inhibitors, DILI, myeloproliferative neoplasia

Abstract

Different drugs can cause different types of liver damage. Those related to immune control can trigger acute autoimmune-
like liver damage, similar to acute autoimmune hepatitis or reactivation of chronic inactive hepatitis
B. Tyrosine kinase receptor inhibitors (TKI) are widely used for the treatment of certain diseases through immune
control. We present the case of a patient treated with imatinib, a type of TKI, due to a chronic myeloproliferative
neoplasm with atypical liver damage in the form of rapidly progressive fibrosis.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

National Center for Biotechnology Information: National Library of Medicine.

LiverTox: clinical and research information on drug-induced liver

injury. Bethesda (MD): National Institute of Diabetes and Digestive and

Kidney Diseases. 2012. Accesible en: https://www.ncbi.nlm.nih.gov/books/

NBK547959/ (último acceso oct. 2024).

Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mandó OG.

Imatinib-induced fatal acute liver failure. World journal of gastroenterology.

; 13(48): 6608–6611. doi: https://doi.org/10.3748/wjg.v13.i48.6608 DOI: https://doi.org/10.3748/wjg.v13.i48.6608

(último acceso oct. 2024).

Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, et al. Chronic myeloid

leukemia patient manifesting fatal hepatitis B virus reactivation during

treatment with imatinib rescued by liver transplantation: case report and

literature review. International journal of hematology. 2009; 90(3): 383–387.

https://doi.org/10.1007/s12185-009-0386-2 (último acceso oct. 2024). DOI: https://doi.org/10.1007/s12185-009-0386-2

Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G, Dellacasa C, et al.

Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica.

; 91(Suppl 6): ECR27. Accesible en: https://pubmed.ncbi.

nlm.nih.gov/16785130/ (último acceso oct. 2024).

Flynn JP, Gerriets V. Imatinib. StatPearls. Treasure Island (FL): StatPearls

Publishing; 2024. Accesible en: https://www.ncbi.nlm.nih.gov/books/

NBK551676/ (último acceso oct. 2024).

Downloads

PDF (Español (España))

Published

2024-12-31

How to Cite

Blázquez-Ávila V, Rodríguez-Martín L, Álvarez-Cañas MC, de las Heras-Rodríguez N. Imatinib-induced immune-like chronic liver disease. Rev Esp Casos Clin Med Intern [Internet]. 2024 Dec. 31 [cited 2025 Feb. 5];9(3):117-9. Available from: https://www.reccmi.com/RECCMI/article/view/1018

Download Citation

Issue

Vol. 9 No. 3 (2024): Revista Española de Casos Clínicos en Medicina Interna

Section

CLINICAL CASES

License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:

Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.

No comercial: no puede utilizar el material con fines comerciales.

No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.

Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.